Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36945
Title: | Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib | Authors: | Awada, Ahmad Berghmans, Thierry Clement, Paul M. CUPPENS, Kristof De Wilde, Bram Machiels, Jean-Pascal Pauwels , Patrick Peeters , Marc Rottey, Sylvie Van Cutsem , Eric |
Issue Date: | 2022 | Publisher: | ELSEVIER SCIENCE INC | Source: | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 169 (Art N° 103564) | Abstract: | Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type. The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union. This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings. | Notes: | Awada, A (corresponding author), Univ Libre Bruxelles, Jules Bordet Inst, Oncol Med Dept, Rue Heger Bordetstr 1, Brussels, Belgium. ahmad.awada@bordet.be |
Keywords: | Larotrectinib;NTRK gene fusion;Trk inhibitor;Tumor-agnostic;Expert opinion;Oncogene proteins;Protein kinase inhibitors | Document URI: | http://hdl.handle.net/1942/36945 | ISSN: | 1040-8428 | e-ISSN: | 1879-0461 | DOI: | 10.1016/j.critrevonc.2021.103564 | ISI #: | WOS:000760448600013 | Rights: | 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib _ Elsevier Enhanced Reader.pdf | Published version | 4.65 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
11
checked on Oct 6, 2024
Page view(s)
22
checked on Sep 7, 2022
Download(s)
8
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.